TG Therapeutics TGTX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 83.1%-4.4pp | 83.7%-4.6pp | 85.3%-3.0pp | 87%-5.8pp | 87.4%-6.1pp | |
| Operating margin | 21.3%— | 20%— | 19.3%— | —— | —— | |
| Net margin | 66%— | 72.6%— | 84.1%— | —— | —— | |
| Returns | ||||||
| Return on equity | 112.6%— | 102.8%— | 112%— | —— | —— | |
| Return on invested capital | 23.9%— | 22%— | 19.8%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.6×-0.1× | 0.8×0.0× | 0.7×+0.1× | 0.8×-0.3× | 0.8×-0.3× | |
| Liquidity | ||||||
| Current ratio | 5.8×+1.8× | 4.1×-2.1× | 3.8×-0.8× | 3.9×+0.3× | 4×+0.4× | |
| Leverage | ||||||
| Debt-to-equity | 1.3×+0.2× | 0.4×-0.7× | 0.4×-0.9× | 0.9×+0.3× | 1.1×+0.4× | |
| Net debt / EBITDA | 2.1×— | 1.4×— | 1.7×— | —— | —— | |
| Per Share | ||||||
| Book value per share | $3.64+150% | $4.01+189% | $3.77+215% | $1.70+52.7% | $1.46+33.1% | |
| Valuation | ||||||
| Market capitalization | $5.3B-14.3% | $4.73B+1.0% | $5.73B+58.3% | $5.92B+115% | $6.19B+164% | |
| Price / earnings | 11.5×— | 10.6×— | 12.8×— | —— | —— | |
| Price / sales | 7.6×-8.5× | 7.7×-6.6× | 10.8×-2.9× | 13×+5.1× | 16×+7.9× | |
| Price / book | 9.1×-17.0× | 7.3×-13.8× | 9.4×-9.4× | 21.4×+5.9× | 26.1×+11.4× | |
| EV / EBITDA | 37.5×— | 39.8×— | 57.5×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are TG Therapeutics's profit margins?
- TG Therapeutics (TGTX) runs a 83.1% gross margin and a 21.3% operating margin, with a 66.0% net margin.
- Where do TG Therapeutics's ratios come from?
- Every ratio is computed from TG Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
